Free Trial
Joseph Schwartz

Joseph Schwartz Analyst Performance

Senior Research Analyst at Leerink Partners

Joseph Schwartz is a stock analyst at Leerink Partners focused in the medical sector, covering 34 publicly traded companies. Over the past year, Joseph Schwartz has issued 8 stock ratings, including buy and hold recommendations. While full access to Joseph Schwartz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Schwartz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
118 Last 10 Years
Buy Recommendations
78.63% 92 Buy Ratings
Companies Covered
34 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy78.6%92 ratings
Hold17.9%21 ratings
Sell3.4%4 ratings

Out of 117 total stock ratings issued by Joseph Schwartz at Leerink Partners, the majority (78.6%) have been Buy recommendations, followed by 17.9% Hold and 3.4% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
34 companies

Joseph Schwartz, an analyst at Leerink Partners, currently covers 34 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
30 companies
88.2%
Miscellaneous
4 companies
11.8%

Joseph Schwartz of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
15 companies
44.1%
PHARMACEUTICAL PREPARATIONS
11 companies
32.4%
Miscellaneous
4 companies
11.8%
MED - DRUGS
3 companies
8.8%
BIOTECHNOLOGY
1 company
2.9%

About Joseph Schwartz

Joseph Schwartz is a Senior Research Analyst at Leerink Partners covering Rare Diseases. Prior to joining the Firm in 2003, Joseph provided economic and strategic consulting services to biotechnology and pharmaceutical companies with Charles River Associates. Earlier in his career, he held equity research positions at SG Cowen, State Street Research, and J.P. Morgan, where he analyzed the fundamental performance drivers of investments in the health care, retail, consumer, media, and entertainment sectors. He was named #1 Stock Picker for Pharmaceuticals in the 2011 FT/StarMine Analyst Awards. In 2010, he earned the Wall Street Journal’s #1 ranking for biotech stock picking as part of its “Best on the Street” analysts survey, which topped his #2 ranking in the Journal’s 2008 “Best on the Street” rankings. He earned an M.B.A. from Babson College and a B.A. in Economics from Colby College.
Follow on LinkedIn

Joseph Schwartz's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
9/29/2025Boost Price Target$45.91$88.00Outperform
uniQure N.V. stock logo
QURE
uniQure
9/24/2025Boost Price Target$44.02$68.00Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
9/9/2025Boost Price Target$17.72$15.00Market Perform
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
7/7/2025Boost Price Target$15.06$20.00Outperform
Insmed, Inc. stock logo
INSM
Insmed
6/10/2025Boost Price Target$90.94$115.00Outperform
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
5/23/2025Upgrade$6.12$12.00Outperform
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
4/30/2025Reiterated Rating$7.98$7.00Market Perform
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
2/25/2025Initiated Coverage$10.82$28.00Outperform